Anal Carcinoma: 357 Clinical Trials, Page 24 of 36

Hide Studies Not Open or Pending

234

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Condition(s):Carcinoma, Non-Small-Cell Lung; Cutaneous Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Nasopharyngeal Carcinoma; Carcinoma, Thymic; Anal Cancer; Mesothelioma; Esophagogastric Cancer; High Microsatellite Instability Colorectal Carcinoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast NeoplasmsLast Updated:March 25, 2024Recruiting

235

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Condition(s):Thyroid; Renal Cell Carcinoma; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Melanoma; Merkel Cell Carcinoma; Skin Squamous Cell Carcinoma; Microsatellite Instability High; Triple Negative Breast Cancer; Mesothelioma; Thymic Cancer; Cervical Cancer; Biliary Tract Cancer; Hepatocellular Carcinoma; Ovarian Cancer; Gastric Cancer; Head and Neck Squamous Cell Carcinoma; Anal CancerLast Updated:March 7, 2024Active, not recruiting

238

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Condition(s):Advanced Cancer; Anal Carcinoma; Anal Cancer; Biliary Cancer; Cholangiocarcinoma; Bile Duct Cancer; Neuroendocrine Tumor; Carcinoid Tumor; Endometrial Carcinoma; Endometrial Cancer; Cervical Carcinoma; Cervical Cancer; Vulvar Carcinoma; Vulvar Cancer; Small Cell Lung Carcinoma; Small Cell Lung Cancer (SCLC); Mesothelioma; Thyroid Carcinoma; Thyroid Cancer; Salivary Gland Carcinoma; Salivary Gland Cancer; Salivary Cancer; Parotid Gland Cancer; Advanced Solid Tumors; Colorectal CarcinomaLast Updated:February 5, 2024Recruiting

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.